Table 4.
Vaccination status and vaccine used.
| Patient | Total Population N (%) | 2015 and 2016 Age Group N (%) | 2017 and 2018 Age Group N (%) | p | Cramér’s V | |
|---|---|---|---|---|---|---|
| Vaccinated against pneumococcus | Yes | 1168 (73.2) | 456 (60.4) | 712 (84.8) | <0.001 | 0.275 |
| No | 427 (26.8) | 299 (39.6) | 128 (15.2) | |||
| Vaccination schedule | Completed | 1168 (73.2) | 456 (60.4) | 712 (84.8) | <0.001 | 0.346 |
| Not completed | 189 (11.8) | 89 (11.8) | 100 (11.9) | |||
| No vaccination | 238 (15.0) | 210 (27.8) | 28 (3.3) | |||
| Product (N = 1357) | PCV10 1 | 801 (59.0) | 151 (27.7) | 650 (80.1) | <0.001 | 0.521 |
| PCV13 2 | 556 (41.0) | 394 (72.3) | 162 (19.9) | |||
1 PCV10—10-valent conjugate pneumococcal vaccine; 2 PCV13—13-valent conjugate pneumococcal vaccine.